Company news

Nanexa AB news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables

September 25, 2026

Nanexa publishes interim report for April - June 2026

August 27, 2026

Nanexa publishes interim report for January-March 2026

April 29, 2026

Nanexa resolves on set-off of outstanding loan

April 28, 2026

Nanexa announces exercise of warrants

April 2, 2026

Nanexa publishes annual report for 2025

March 26, 2026

Nanexa publishes year-end report and Q4 report 2025

February 19, 2026

Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation

January 27, 2026

Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products

December 10, 2025

Nanexa publishes interim report for January-September 2025

November 6, 2025

Nanexa AB changes Certified Adviser to Tapper Partners AB

October 1, 2025

Nanexa receives Japanese patent approval for specific PharmaShell structure

September 22, 2025

Nanexa publishes interim report for January-June 2025

August 27, 2025

Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell® Long-Acting Formulations in a Multi-Billion USD Market

August 8, 2025

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks